Brought to you by 
ARCA biopharma, Nuvelo in reverse merger
16 Jun 2021
Executive Summary
Heart disease company ARCA biopharma is going public by merging with Nuvelo (cancer and cardiovascular diseases) in a stock swap. ARCA shareholders will own about 67% of the newly combined company, which will focus on cardiovascular therapeutics. The combination will take ARCA's name.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ARCA biopharma, Nuvelo in reverse merger
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice